Table 1.

In vitro expansion of Vγ9Vδ2-TCR⁺ γδT cells from PBMC of healthy donors in response to zoledronate.

Treatment	PBMC		CD25+ depleted
	IL-2	IL-2/IL-15	IL-2	IL-2/IL-15
Donors	6	13	6	12
Input of Vγ9+ T cells (×106/106 PBMC)a	0.019 ± 0.010	0.021 ± 0.011	0.019 ± 0.010	0.022 ± 0.012
DAY 14 CULTURES
Live cells (%)b	71 ± 11	85 ± 11	77 ± 9	87 ± 6
CD3+ cells (%)c	92 ± 10	96 ± 3	94 ± 4	95 ± 4
Vγ9+ T cells (%)c	56 ± 27	77 ± 21	62 ± 22	74 ± 18
Yield of Vγ9+ T cells (×106/106 PBMC)d	2 ± 1.2	29 ± 10.4	2.9 ± 0.94	23 ± 8.7
Expansion folde	104 ± 120	1370 ± 949	150 ± 94	1025 ± 721

^a Initiation of cultures at 10⁶ PBMC per well (24-well plate).

^b Live cells defined as Aqua⁻ cells.

^c Percentage of total live (Aqua⁻) cells.

^d Number of Vγ9⁺ T cells per 10⁶ of input PBMC after 14 days of culture.

^e Yield of Vγ9⁺ T cells divided by input Vγ9⁺ T cells.